# Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

> **NCT04454489** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 21 (actual)

## Conditions studied

- Advanced Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Pembrolizumab (immunotherapy)
- **RADIATION:** Quad-shot palliative radiotherapy

## Key facts

- **NCT ID:** NCT04454489
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-25
- **Primary completion:** 2025-02-18
- **Final completion:** 2025-04-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04454489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04454489, "Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04454489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*